{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T18:05:13Z","timestamp":1775930713894,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","award":["2018"],"award-info":[{"award-number":["2018"]}],"id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A wide range of rare diseases can have fiscal impacts on government finances that extend beyond expected healthcare costs. Conditions preventing people from achieving national lifetime work averages will influence lifetime taxes paid and increase the likelihood of dependence on public income support. Consequently, interventions that influence projected lifetime work activity, morbidity and mortality can have positive and negative fiscal consequences for government. The aim of this study was to apply a public economic framework to a rare disease that takes into consideration a broad range of costs that are relevant to government in relation to transfers received and taxes paid. As a case study we constructed a simulation model to calculate the fiscal life course of an individual with hereditary transthyretin-mediated (hATTR) amyloidosis in The Netherlands. In this lethal disease different progressive disease scenarios occur, including polyneuropathy and\/or cardiomyopathy.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Due to progressive disability, health care resource use, and early death, hATTR amyloidosis with polyneuropathy receives more transfers from government compared to the general population. In a scenario where a patient is diagnoses with hATTR at age 45, an individual pays \u20ac180,812 less in lifetime taxes and receives incrementally \u20ac111,695 in transfers from the government, compared to a person without hATTR. Patients suffering from cardiomyopathy die after median 4\u2009years. The health costs of this scenario are therefore lower than that of the other polyneuropathy-based scenarios.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The fiscal analysis illustrates how health conditions influence not only health costs, but also the cross-sectorial public economic burden attributed to lost tax revenues and public disability allowances. Due to the progressive nature of hATTR amyloidosis used in this study, public costs including disability increase as the disease progresses with reduced lifetime taxes paid. The results indicate that halting disease progression early in the disease course would generate fiscal benefits beyond health benefits for patients. This analysis highlights the fiscal consequences of diseases and the need for broader perspectives applied to evaluate health conditions. Conventional cost-effectiveness framework used by many health technology assessment agencies have well-documented limitations in the field of rare diseases and fiscal modeling should be a complementary approach to consider.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-019-1199-x","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T14:07:31Z","timestamp":1568815651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-745X","authenticated-orcid":false,"given":"Mark P.","family":"Connolly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3491-8093","authenticated-orcid":false,"given":"Saswat","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Patris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1827-0482","authenticated-orcid":false,"given":"Bouke P. C.","family":"Hazenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"issue":"2","key":"1199_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jval.2016.11.018","volume":"20","author":"MP Connolly","year":"2017","unstructured":"Connolly MP, Kotsopoulos N, Postma MJ, Bhatt A. The fiscal consequences attributed to changes in morbidity and mortality linked to Investments in Health Care: a government perspective analytic framework. Value Health. 2017;20(2):273\u20137.","journal-title":"Value Health"},{"issue":"1","key":"1199_CR2","doi-asserted-by":"publisher","first-page":"23897","DOI":"10.3402\/jmahp.v2.23897","volume":"2","author":"N Kotsopoulos","year":"2014","unstructured":"Kotsopoulos N, Connolly MP. Is the gap between micro-and macroeconomic assessments in health care well understood? The case of vaccination and potential remedies. J Mark Access Health Policy. 2014;2(1):23897.","journal-title":"J Mark Access Health Policy"},{"issue":"6","key":"1199_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/13696998.2018.1434183","volume":"21","author":"MP Connolly","year":"2018","unstructured":"Connolly MP, Baker CL, Kotsopoulos N. Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework. J Med Econ. 2018;21(6):571\u20136.","journal-title":"J Med Econ"},{"key":"1199_CR4","unstructured":"Health resources - Health spending - OECD Data [\n                    https:\/\/data.oecd.org\/healthres\/health-spending.htm\n                    \n                  ]. Accessed 9 May 2019."},{"key":"1199_CR5","doi-asserted-by":"crossref","unstructured":"Figari F, Paulus A, Sutherland H. Chapter 24 - microsimulation and policy analysis. In: Atkinson AB, Bourguignon F, editors. Handbook of Income Distribution, vol. 2: Elsevier; 2015. p. 2141\u2013221. \n                    https:\/\/www.econstor.eu\/bitstream\/10419\/197586\/1\/1040420044.pdf\n                    \n                  .","DOI":"10.1016\/B978-0-444-59429-7.00025-X"},{"issue":"2 Pt 2","key":"1199_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1475-6773.12052","volume":"48","author":"JM Abraham","year":"2013","unstructured":"Abraham JM. Using microsimulation models to inform U.S. health policy making. Health Serv Res. 2013;48(2 Pt 2):686\u201395.","journal-title":"Health Serv Res"},{"issue":"3","key":"1199_CR7","first-page":"33","volume":"4","author":"D Schofield","year":"2011","unstructured":"Schofield D, Shrestha R, Callander E, Percival R, Kelly S, Passey M, Fletcher S. Modelling the cost of ill health in health&WealthMOD (version II): lost labour force participation, income and taxation, and the impact of disease prevention. Int J Microsimulation. 2011;4(3):33\u20137.","journal-title":"Int J Microsimulation"},{"key":"1199_CR8","volume-title":"Modelling our future: population ageing health and aged care","author":"AA Richard Percival","year":"2007","unstructured":"Richard Percival AA, Quoc N. Vu: Model 9: STINMOD (Static Incomes Model). In: Modelling our future: population ageing health and aged care. 1st. Edited by Gupta A, Harding A. Amsterdam; Boston: Elsevier; 2007.","edition":"1"},{"issue":"1","key":"1199_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1257\/jep.8.1.73","volume":"8","author":"AJ Auerbach","year":"1994","unstructured":"Auerbach AJ, Gokhale J, Kotlikoff LJ. Generational accounting: a meaningful way to evaluate fiscal policy. J Econ Perspect. 1994;8(1):73\u201394.","journal-title":"J Econ Perspect"},{"issue":"2","key":"1199_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.socscimed.2011.05.027","volume":"73","author":"P-C Michaud","year":"2011","unstructured":"Michaud P-C, Goldman D, Lakdawalla D, Gailey A, Zheng Y. Differences in health between Americans and Western Europeans: effects on longevity and public finance. Soc Sci Med. 2011;73(2):254\u201363.","journal-title":"Soc Sci Med"},{"issue":"2","key":"1199_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.17310\/ntj.2010.2.07","volume":"63","author":"D Goldman","year":"2010","unstructured":"Goldman D, Michaud P-C, Lakdawalla D, Zheng Y, Gailey A, Vaynman I. The fiscal consequences of trends in population health. Natl Tax J. 2010;63(2):307.","journal-title":"Natl Tax J"},{"issue":"7 Suppl","key":"1199_CR12","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107\u2013s112.","journal-title":"Am J Manag Care"},{"issue":"1","key":"1199_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon B-G, Ikeda S-i, Lewis WD, Obici L, Plant\u00e9-Bordeneuve V, Rapezzi C, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8(1):31.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1199_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11897-013-0182-4","volume":"11","author":"M Hanna","year":"2014","unstructured":"Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50\u20137.","journal-title":"Curr Heart Fail Rep"},{"issue":"9","key":"1199_CR15","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, Obici L, Westermark P, Grateau G, Wechalekar AD. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403\u201312.","journal-title":"Hum Mutat"},{"issue":"6","key":"1199_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/msj.21352","volume":"79","author":"SC Shin","year":"2012","unstructured":"Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med New York. 2012;79(6):733\u201348.","journal-title":"Mt Sinai J Med New York"},{"issue":"1","key":"1199_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mus.20644","volume":"35","author":"I Concei\u00e7\u00e3o","year":"2007","unstructured":"Concei\u00e7\u00e3o I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 2007;35(1):116\u20138.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1199_CR18","doi-asserted-by":"publisher","first-page":"A287","DOI":"10.1016\/j.jval.2015.03.1672","volume":"18","author":"RN Denoncourt","year":"2015","unstructured":"Denoncourt RN, Adams D, Coelho T, Bettencourt BR, Plaisted A, Amitay O, Falzone R, Harrop J, White L, De Frutos R, et al. Burden of illness for patients with familial amyloidotic polyneuropathy (Fap) begins early and increases with disease progression. Value Health. 2015;18(3):A287.","journal-title":"Value Health"},{"issue":"2","key":"1199_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","volume":"7","author":"M Stewart","year":"2018","unstructured":"Stewart M, Shaffer S, Murphy B, Loftus J, Alvir J, Cicchetti M, Lenderking WR. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7(2):349\u201364.","journal-title":"Neurol Ther"},{"issue":"1","key":"1199_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.amjcard.2017.09.029","volume":"121","author":"SHC Klaassen","year":"2018","unstructured":"Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, van Veldhuisen DJ, Hazenberg BPC. Frequency of and prognostic significance of cardiac involvement at presentation in hereditary transthyretin-derived amyloidosis and the value of N-terminal pro-B-type natriuretic peptide. Am J Cardiol. 2018;121(1):107\u201312.","journal-title":"Am J Cardiol"},{"issue":"21","key":"1199_CR21","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","volume":"91","author":"T Coelho","year":"2018","unstructured":"Coelho T, In\u00eas M, Concei\u00e7\u00e3o I, Soares M, de Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91(21):e1999\u20132009.","journal-title":"Neurology"},{"issue":"2","key":"1199_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","volume":"20","author":"A Casta\u00f1o","year":"2015","unstructured":"Casta\u00f1o A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163\u201378.","journal-title":"Heart Fail Rev"},{"issue":"10","key":"1199_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jval.2018.08.005","volume":"21","author":"J Mauskopf","year":"2018","unstructured":"Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL. Economic analysis of vaccination programs. Value Health. 2018;21(10):1133\u201349.","journal-title":"Value Health"},{"key":"1199_CR24","unstructured":"StatLine - Employment; jobs, wages, working hours; key figures [\n                    https:\/\/opendata.cbs.nl\/#\/CBS\/en\/dataset\/81431ENG\/table?ts=1529671314235\n                    \n                  ]. Accessed 9 May 2019."},{"key":"1199_CR25","unstructured":"StatLine - Labour participation; key figures [\n                    https:\/\/opendata.cbs.nl\/#\/CBS\/en\/dataset\/82309ENG\/table?ts=1529670397747\n                    \n                  ]. Accessed 9 May 2019."},{"key":"1199_CR26","unstructured":"U hebt in 2018 de AOW-leeftijd nog niet bereikt [\n                    https:\/\/www.belastingdienst.nl\/wps\/wcm\/connect\/bldcontentnl\/belastingdienst\/prive\/inkomstenbelasting\/heffingskortingen_boxen_tarieven\/boxen_en_tarieven\/overzicht_tarieven_en_schijven\/u-hebt-in-2018-de-aow-leeftijd-nog-niet-bereikt\n                    \n                  ]. Accessed 9 May 2019."},{"key":"1199_CR27","unstructured":"StatLine - Inkomensverdeling van huishoudens; nr, 2005-2014. [\n                    https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/82959NED\/table?ts=1532525633247\n                    \n                  ]. Accessed 9 May 2019."},{"key":"1199_CR28","unstructured":"Consumption Tax Trends 2016 - the Netherlands [\n                    https:\/\/www.oecd.org\/tax\/consumption\/consumption-tax-trends-netherlands.pdf\n                    \n                  ]. Accessed 9 May 2019."},{"key":"1199_CR29","unstructured":"OECD. OECD Economic Surveys, vol. 2018. Netherlands: OECD Publishing; 2018."},{"key":"1199_CR30","unstructured":"World Bank, Inflation, consumer prices for the Netherlands [FPCPITOTLZGNLD]. 2019. \n                    https:\/\/fred.stlouisfed.org\/series\/FPCPITOTLZGNLD\n                    \n                  . Accessed 9 May 2019."},{"key":"1199_CR31","unstructured":"Wanneer krijgt u AOW | AOW | SVB [\n                    https:\/\/www.svb.nl\/int\/nl\/aow\/wat_is_de_aow\/wanneer_aow\/index.jsp\n                    \n                  ]. Accessed 9 May 2019."},{"issue":"3","key":"1199_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/0141076817690395","volume":"110","author":"L Garattini","year":"2017","unstructured":"Garattini L, Padula A. Dutch guidelines for economic evaluation:\u2018from good to better\u2019in theory but further away from pharmaceuticals in practice? J R Soc Med. 2017;110(3):98\u2013103.","journal-title":"J R Soc Med"},{"key":"1199_CR33","unstructured":"PAID - iMTA [\n                    https:\/\/www.imta.nl\/paid\n                    \n                  ]. Accessed 9 May 2019."},{"issue":"3","key":"1199_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","volume":"29","author":"PH van Baal","year":"2011","unstructured":"van Baal PH, Wong A, Slobbe LC, Polder JJ, Brouwer WB, de Wit GA. Standardizing the inclusion of indirect medical costs in economic evaluations. PharmacoEconomics. 2011;29(3):175\u201387.","journal-title":"PharmacoEconomics"},{"key":"1199_CR35","unstructured":"CBS Statline [\n                    https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/82959NED\/table?ts=1532525633247\n                    \n                  ]. Accessed 9 May 2019."},{"key":"1199_CR36","unstructured":"Mijn geldzaken tijdens WAO | UWV | Particulieren [\n                    https:\/\/www.uwv.nl\/particulieren\/ziek\/ziek-wao-uitkering\/geldzaken-tijdens-wao\/detail\/hoogte-en-duur-van-een-wao-uitkering\/arbeidsongeschiktheidsklasse-bij-wao\n                    \n                  ]. Accessed 9 May 2019."},{"issue":"2","key":"1199_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/1756285612470192","volume":"6","author":"D Adams","year":"2012","unstructured":"Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord. 2012;6(2):129\u201339.","journal-title":"Ther Adv Neurol Disord"},{"issue":"Suppl 1","key":"1199_CR38","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14\u201326.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"1199_CR39","first-page":"10","volume":"2","author":"HLA Nienhuis","year":"2016","unstructured":"Nienhuis HLA, Bijzet J, Hazenberg BPC. The prevalence and Management of Systemic Amyloidosis in Western countries. Kidney Dis (Basel, Switzerland). 2016;2(1):10\u20139.","journal-title":"Kidney Dis (Basel, Switzerland)"},{"issue":"1","key":"1199_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-017-0601-9","volume":"12","author":"L Annemans","year":"2017","unstructured":"Annemans L, Ayme S, Le Cam Y, Facey K, Gunther P, Nicod E, Reni M, Roux JL, Schlander M, Taylor D, et al. Recommendations from the European working Group for Value Assessment and Funding Processes in rare diseases (ORPH-VAL). Orphanet J Rare Dis. 2017;12(1):50.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1199_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13023-016-0555-3","volume":"12","author":"C Schey","year":"2017","unstructured":"Schey C, Krabbe PFM, Postma MJ, Connolly MP. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet J Rare Dis. 2017;12(1):10.","journal-title":"Orphanet J Rare Dis"},{"key":"1199_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13023-015-0269-y","volume":"10","author":"L Gutierrez","year":"2015","unstructured":"Gutierrez L, Patris J, Hutchings A, Cowell W. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis. 2015;10:53.","journal-title":"Orphanet J Rare Dis"},{"key":"1199_CR43","unstructured":"Social Protection Statistics 2015 [\n                    https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php\/Social_protection_statistics#Social_protection_expenditure_and_GDP_rates_of_change\n                    \n                  ]. Accessed 9 May 2019."},{"key":"1199_CR44","unstructured":"State of Health in the EU Netherlands Country Health Profile 2017 [\n                    https:\/\/ec.europa.eu\/health\/sites\/health\/files\/state\/docs\/chp_nl_english.pdf\n                    \n                  ]. Accessed 9 May 2019."},{"issue":"1","key":"1199_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2017.1371032","volume":"21","author":"MP Connolly","year":"2018","unstructured":"Connolly MP, Kotsopoulos N, Ustianowski A. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C. J Med Econ. 2018;21(1):19\u201326.","journal-title":"J Med Econ"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1199-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T23:29:15Z","timestamp":1600298955000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1199-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not involve any primary data collection and no patient level data is included.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors SP, MPC, and BPH hold no financial interests in the sponsoring organisation. The results described here do not contain any product specific names or literature from the sponsoring company. The authors declare no competing interests in relation to the work described here.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}